{"filing":{"accession_number":"0001193125-26-276718","cik":"0001628171","ticker":"RVMDW","company_name":"Revolution Medicines, Inc.","form":"8-K","filing_date":"2026-06-22","report_date":null,"primary_document":"d123125d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1628171/000119312526276718/d123125d8k.htm"},"events":[{"id":12599,"run_id":11176,"accession_number":"0001193125-26-276718","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"Dr. Steve Kelsey, President of Research and Development, informed the Company of his intent to retire from employment effective January 4, 2027, with a transition to senior advisor role beginning July 1, 2026.","company_name":"Revolution Medicines, Inc.","ticker":"RVMDW","filing_date":"2026-06-22","form":"8-K","submitted_at":null,"items":[{"id":9492,"accession_number":"0001193125-26-276718","item_number":"5.02","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"Dr. Steve Kelsey, the Company's president of research and development, has informed the Company of his intent to retire from employment effective January 4, 2027. While the disclosure also mentions a transition to senior advisor (July 1, 2026) and contemplated board appointment, the principal disclosed action is the departure of a named executive officer from his current operational role. The retirement from employment is the material event, even though a board appointment may follow.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T12:01:33.143795+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":12600,"run_id":11176,"accession_number":"0001193125-26-276718","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Revolution Medicines held its annual stockholder meeting on June 18, 2026, with shareholders voting on the election of two Class III directors (Alexis Borisy and Mark A. Goldsmith, M.D., Ph.D.), ratification of PricewaterhouseCoopers LLP as independent auditor, and advisory approval of named executive officer compensation.","company_name":"Revolution Medicines, Inc.","ticker":"RVMDW","filing_date":"2026-06-22","form":"8-K","submitted_at":null,"items":[{"id":9493,"accession_number":"0001193125-26-276718","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Item 5.07 discloses the results of Revolution Medicines' June 18, 2026 annual stockholder meeting, including voting outcomes on three proposals: election of two Class III directors (Alexis Borisy and Mark A. Goldsmith, M.D., Ph.D.), ratification of PricewaterhouseCoopers LLP as independent auditor, and advisory approval of named executive officer compensation. The tabulated vote counts for each proposal are provided in detail, which is the core disclosure required under Item 5.07 for shareholder vote results.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T12:01:33.143795+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":9492,"accession_number":"0001193125-26-276718","item_number":"5.02","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"Dr. Steve Kelsey, the Company's president of research and development, has informed the Company of his intent to retire from employment effective January 4, 2027. While the disclosure also mentions a transition to senior advisor (July 1, 2026) and contemplated board appointment, the principal disclosed action is the departure of a named executive officer from his current operational role. The retirement from employment is the material event, even though a board appointment may follow.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T12:01:33.143795+00:00","company_name":"Revolution Medicines, Inc.","ticker":"RVMDW","filing_date":"2026-06-22"},{"id":9493,"accession_number":"0001193125-26-276718","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Item 5.07 discloses the results of Revolution Medicines' June 18, 2026 annual stockholder meeting, including voting outcomes on three proposals: election of two Class III directors (Alexis Borisy and Mark A. Goldsmith, M.D., Ph.D.), ratification of PricewaterhouseCoopers LLP as independent auditor, and advisory approval of named executive officer compensation. The tabulated vote counts for each proposal are provided in detail, which is the core disclosure required under Item 5.07 for shareholder vote results.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T12:01:33.143795+00:00","company_name":"Revolution Medicines, Inc.","ticker":"RVMDW","filing_date":"2026-06-22"}]}